Conference Coverage

ZO-FAST: Immediate Zoledronic Acid Beats Delayed Tx in Early Breast Cancer

Publish date: December 8, 2011

 

FROM THE SAN ANTONIO BREAST CANCER SYMPOSIUM

Dr. de Boer is on the speakers’ bureau for Novartis. Dr. Ingle said he had no financial conflicts to disclose.

Pages

Recommended Reading

BOLERO-2: Everolimus Plus Exemestane Delays Breast Cancer Progression
MDedge Internal Medicine
Breast Cancer Gene Profile Identifies Early vs. Late Recurrences
MDedge Internal Medicine
Zoledronic Acid's Breast Cancer Benefit Extends 7 Years
MDedge Internal Medicine
FDA Drops Restrictions for Thrombocytopenia Treatments
MDedge Internal Medicine
IOM Dissects Environmental Risk Factors for Breast Cancer
MDedge Internal Medicine
Dual HER2 Blockade Defers Breast Cancer Progression
MDedge Internal Medicine
DCIS Assay Predicts Recurrence Risk After Breast Surgery
MDedge Internal Medicine
Clodronate Offered Modest Benefit for Breast Cancer Patients
MDedge Internal Medicine
Panel Endorses Surveillance for Low-Risk Prostate Cancer
MDedge Internal Medicine
Medicare Study Confirms Colonoscopy's Cancer Prevention Power
MDedge Internal Medicine